Table 4.

Descriptive statistics in treated with ALCAR 1.5 g/day and matched not treated

	Not treated		Treated with ALCAR 1.5 g/day		p value
	n	%	n	%
Sex					> 0.9999
Female	11	24.4	11	24.4
Male	34	75.6	34	75.6
Site of onset					> 0.9999
Bulbar	13	28.9	13	28.9
Spinal	32	71.1	32	71.1
El Escorial category					0.0408
Definite	6	13.3	16	35.6
Probable	18	40.0	15	33.3
Probable laboratory supported	21	46.7	14	31.1
Riluzole use					0.0910
Yes	40	88.9	44	97.8
No	5	11.1	1	2.2
Progression rate					0.1282
Fast	13	28.9	7	15.6
Slow	32	71.1	38	84.4

	Not treated		Treated with ALCAR 1.5 g/day		p value
	Median	IQR	Median	IQR
Age onset	64.8	55.9–71.4	63.8	56.1–69.1	0.8155
Age diagnosis	65.4	56.8–71.9	64.9	57.8–70.1	0.9295
Diagnostic delay	8.3	5.1–10.8	10.6	5.0–14.3	0.0913
Follow up duration	25.8	18.9–49.6	33.6	22.4–47.7	0.2424
Progression rate at diagnosis	0.46	0.28–0.74	0.28	0.15–0.52	0.0067
Age baseline	65.4	56.8–72.0	65.0	57.8–70.1	0.9359
Time from diagnosis to baseline (months)	0.0	0.0–0.9	0.0	0.0–0.0	0.4410
ALSFRS-R	44	41–46	45	44–46	0.0614
FVC %	96	93–105	97	89–102	0.4146

ALCAR acetyl-l-carnitine, FVC forced vital capacity, ALSFRS-R amyotrophic lateral sclerosis functional rating scale-revised